Explanipedia

15P Germline predictors of recurrence in patients with ER-positive and HER2-negative breast cancer: A GWAS analysis of multiple cohorts totaling 10,640 patients Open

É. Turcotte, Emilie Thomas, X. Pivot, Inês Machado Vaz, J.-F. Deleuze , et al. · 2024

Renal toxicity of ifosfamide in children with cancer: an exploratory study integrating aldehyde dehydrogenase enzymatic activity data and a wide-array urinary metabolomics approach Open

Olivia Febvey‐Combes, Jérôme Guitton, Perrine Marec‐Bérard, Cécile Faure‐Conter, Ellen Blanc , et al. · 2024

Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma Open

Manon De Vries-Brilland, Nathalie Rioux‐Leclercq, Maxime Meylan, Jonathan Dauvé, Christophe Passot , et al. · 2023

Background Papillary renal cell carcinoma (pRCC) is the most common non-clear cell RCC, and associated with poor outcomes in the metastatic setting. In this study, we aimed to comprehensively evaluate the immune tumor microenvironment (TME…

A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein βig-h3 Open

Christelle de la Fouchardière, Pia Gamradt, Sylvie Chabaud, Maxime Raddaz, Ellen Blanc , et al. · 2022

With an overall survival rate of 2–9% at 5 years, pancreatic ductal adenocarcinoma (PDAC) is currently the fourth leading cause of cancer-related deaths in the industrialized world and is predicted to become the second by 2030. Owing to of…

Hypofractionated stereotactic body radiation therapy (SBRT) in pediatric patients: preliminary toxicity results of a national prospective multicenter study Open

Dario Di Perri, Emmanuel Jouglar, Ellen Blanc, Anne Ducassou, A. Huchet , et al. · 2021

Objectives: While hypofractionated stereotactic body radiotherapy (SBRT) has been largely adopted in the adult setting, its use remains limited in pediatric patients. This is due, among other factors, to fear of potential toxicities of hyp…

Analysis of the StoRM cohort reveals physical activity to be associated with survival in metastatic breast cancer Open

Lidia Delrieu, Emmanuelle Jacquet, Céline Ségura‐Ferlay, Ellen Blanc, Olivia Febvey‐Combes , et al. · 2020

Benefits of physical activity are widely demonstrated for early stage cancers but few studies have focused on metastatic disease. The purpose of this study was to determine the impact of physical activity on survival in patients with metas…

Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial Open

Sylvie Négrier, N. Costedoat‐Chalumeau, Céline Ferlay, Marine Gross‐Goupil, Gwénaëlle Gravis , et al. · 2020

Étude randomisée monocentrique évaluant l’efficacité de l’ostéopathie dans la prise en charge des douleurs chroniques après chirurgie mammaire en oncologie Open

Gisèle Chvetzoff, Audrey Berthier, Ellen Blanc, Valérie Bourne Branchu, Anne Millaret , et al. · 2019

Issue Information ‐ TOC Open

Mohammad Y. Zaidi, Alexandra G. Lopez‐Aguiar, George A. Poultsides, Mary Dillhoff, Flavio G. Rocha , et al. · 2018

Using a mul -ins tu onal database, this study found that for pa ents with func onal neuroendocrine tumors, the failure to achieve symptom improvement a er the resec on is associated with earlier disease recurrence even when accoun ng for h…

Efficacy and safety of axitinib in metastatic papillary renal carcinoma (mPRC): Results of a GETUG multicenter phase II trial (Axipap) Open

Sylvie Négrier, N. Costedoat‐Chalumeau, Alain Ravaud, Gwénaëlle Gravis, Lionnel Geoffrois , et al. · 2018

Background: PRC represents 10-15% of renal carcinomas; there is no standard treatment at the metastatic stage. Few trials were conducted with sunitinib, everolimus and more recently savolitinib, with disappointing response rates. Axitinib,…

HEPATOFLUO: A prospective monocentric study assessing the benefits of indocyanine green (ICG) fluorescence for hepatic surgery Open

Aurélien Dupré, Ellen Blanc, Michel Rivoire, David Pérol, Stéphanie Guillermet , et al. · 2018

The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: a marker of response to antitumoural treatment in metastatic renal cell carcinoma Open

Helena Polena, Julie Creuzet, Maeva Dufies, Adama Sidibé, Abir Khalil‐Mgharbel , et al. · 2018

These data highlight the interest for the sVE bioassay in future follow-up of cancer patients treated with targeted therapies such as tyrosine-kinase inhibitors.

SToRM: A clinical cohort to identify genetic variability related to metastatic phenotypes Open

David G. Cox, Ellen Blanc, Gilles Romieu, María Rios, C. Bécuwe , et al. · 2017

Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors Open

Sylvie Négrier, David Pérol, Rastislav Bahleda, Antoine Hollebecque, Étienne Chatelut , et al. · 2017

The study was retrospectively registered on ClinicalTrials.gov (number NCT01202032 ) on 2010, Sept 14th.

Efficacy of high-intensity focused ultrasound-assisted hepatic resection (HIFU-AR) on blood loss reduction in patients with liver metastases requiring hepatectomy: study protocol for a randomized controlled trial Open

Aurélien Dupré, David Pérol, Ellen Blanc, Patrice Peyrat, Valéria Basso , et al. · 2017

Efficacy of continuous wound infiltration of ropivacaïne after liver surgery. Results from a randomized double-blind controlled trial Open

Aurélien Dupré, Véronique Peres‐Bachelot, Patrice Peyrat, Pierre Méeus, Nadia Oussaid , et al. · 2016

A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma Open

Élodie Jobard, Ellen Blanc, Sylvie Négrier, Bernard Escudier, Gwénaëlle Gravis , et al. · 2015

In mRCC, metabolomics shows a faster host metabolism modification induced by a mTOR inhibitor as compared with standard treatments. These results should be confirmed in larger cohorts and other cancer types.

Ellen Blanc YOU? Author Swipe